|
Canada-0-Mosques ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Pulse Biosciences – Powering the next generation in bioelectric . . .
Pulse Biosciences, developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study
- Investor Relations | Pulse Biosciences Inc.
The Investor Relations website contains information about Pulse Biosciences Inc 's business for stockholders, potential investors, and financial analysts
- Pulse Biosciences Reports Business Updates and First Quarter 2024 . . .
The Investor Relations website contains information about Pulse Biosciences Inc 's business for stockholders, potential investors, and financial analysts
- Press Releases - Pulse Biosciences Inc.
The Investor Relations website contains information about Pulse Biosciences Inc 's business for stockholders, potential investors, and financial analysts
- Quarterly Results - Pulse Biosciences Inc.
The Investor Relations website contains information about Pulse Biosciences Inc 's business for stockholders, potential investors, and financial analysts
- Technology – Pulse Biosciences
The cascade of intracellular disruption leads to regulated cell death (RCD) RCD is a process exhibited by cells in the human body when they undergo stress and are unable to restore cellular homeostasis Pulse Biosciences has brought to market the first commercial product to harness the distinctive advantages of nsPFA technology
- Pulse Biosciences Schedules Fourth Quarter Full Year 2025 Financial . . .
HAYWARD, Calif -- (BUSINESS WIRE)--Feb 4, 2026-- Pulse Biosciences, Inc (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026
- Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors . . .
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue
- Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer . . .
MIAMI -- (BUSINESS WIRE)--Feb 4, 2025-- Pulse Biosciences, Inc (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025
- Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse . . .
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue
|
|